Business
EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies
BOSTON, October 16, 2025--EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, and President Donald J. Trump’s administration, today announced an agreement to expand access to the company’s portfolio of in vitro fertilization (IVF) therapies for the more than 10 million American women struggling to have a baby.
About this update from Merck Kgaa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":278,"url":"https://media.zenfs.com/en/business-wire.com/b78b093eeaceb2d05f960c3f80334599"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gCNDyByimvonr9vRDdgKxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU1NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b78b093eeaceb2d05f960c3f80334599","width":480,"height":278}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Voluntary agreement meets the White House Executive Order on increasing access to EMD Serono’s approved IVF treatments and confirms America’s public policy leadership in helping families navigate a path to parenthood","length":216,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"To expand therapeutic options for patients with complex fertility issues, EMD Serono will file Pergoveris for review under the FDA Commissioner's National Priority Voucher program","length":183,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"EMD Serono has entered an agreement with the U.S. Secretary of Commerce to exclude its pharmaceutical products and ingredients from Section 232 tariffs","length":151,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":550,"olType":false},{"type":"text","content":"Not intended for media outside the U.S. or Canada","length":49,"tagName":"p"},{"type":"text","content":"BOSTON, October 16, 2025--(BUSINESS WIRE)--EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, and President Donald J. Trump’s administration, today announced an agreement to expand access to the company’s portfolio of in vitro fertilization (IVF) therapies for the more than 10 million American women struggling to have a baby.","length":371,"tagName":"p"},{"type":"text","content":"As part of the agreement, EMD Serono will offer Direct-to-Consumer (DTC) sales of its complete portfolio of IVF therapies, including Gonal-f® (follitropin alfa injection), Ovidrel® (choriogonadotropin alfa injection), and Cetrotide® (cetrorelix acetate for injection), to eligible patients with prescriptions at significantly reduced prices. When all three therapies are used in a typical IVF protocol, patients will access an 84% discount off list prices. ...